This is a news story, published by Ars Technica, that relates primarily to FDA news.
For more health policy news, you can click here:
more health policy newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about health policy, you might also like this article about
telework. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Review staff news, FDA news, news about health policy, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
FDA policiesArs Technica
•Health
Health
76% Informative
The FDA is reinstating telework for staff who review drugs, medical devices, and tobacco.
Review staff and supervisors are now allowed to resume telework at least two days a week.
The move reverses a return-to-office decree by the Trump administration, which it used to spur resignations.
VR Score
81
Informative language
83
Neutral language
35
Article tone
semi-formal
Language
English
Language complexity
57
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links
